血糖性
2型糖尿病
兴奋剂
2型糖尿病
受体
医学
药效学
胰高血糖素样肽1受体
药理学
内分泌学
连接器
糖尿病
药代动力学
激素
内科学
计算机科学
操作系统
作者
Rami A. Al‐Horani,Milad Chedid
出处
期刊:Endocrine, metabolic & immune disorders
[Bentham Science]
日期:2023-07-01
卷期号:23 (8): 1046-1050
被引量:1
标识
DOI:10.2174/1871530322666221004151212
摘要
Abstract: Tirzepatide (mounjaro®) is a derivative of the human glucose-dependent insulinotropic polypeptide (GIP) hormone with a position-20 being modified with 1,20- eicosanedioic acid via a chemical linker. It acts as a glucagon-like peptide-1 (GLP-1) receptor and GIP receptor agonist. It has recently been approved by FDA as an adjunct therapy to exercise and diet to improve glycemic control in patients with type II diabetes mellitus (T2DM). It represents a new transforming paradigm in the management of T2DM. This mini-review will shed light on its different pharmacokinetic and pharmacodynamic aspects.
科研通智能强力驱动
Strongly Powered by AbleSci AI